Operate with Confidence. Take Control of Bleeding Risk.
The DrugSorb™-ATR device is indicated for the removal of ticagrelor to reduce the severity of perioperative bleeding in patients undergoing coronary artery bypass grafting (CABG) within 2 days of ticagrelor discontinuation.
RE-EVALUATE YOUR CABG RISK
- Bleeding
- Time
- Cost
- Confidence
- Control
Perioperative Bleeding in Cardiac Surgery Due to Ticagrelor Is a Major Unmet Medical Need
Heart attack patients in the hospital are often administered dual anti-platelet therapy, which includes both aspirin and ticagrelor, to reduce the risk of major adverse cardiovascular events like worsened heart attack, stroke, or death.
Although most heart attack patients will go on to receive a stent in the cardiac cath lab, up to 10% of patients will not be eligible for a stent and will require urgent or emergent coronary artery bypass graft (CABG) surgery to restore blood flow to the affected portion of the heart. However, having just received the blood thinner, these patients are at high risk of perioperative bleeding.
Waiting in the hospital to washout the drug over the span of 3-5 days is the only acceptable alternative. But given that the significant blockages in the coronary arteries remain untreated, waiting comes with potential clinical risk for another heart attack or other life-threatening complications like heart failure. In addition, waiting in-hospital for multiple days to get the needed operation adds significant additional costs and blocks beds desperately needed to treat other patients.
With DrugSorb™-ATR, you can reduce the risk of severe bleeding in your CABG surgery patients.
DrugSorb™-ATR is a Powerful New Approach to Treating Patients Undergoing CABG Surgery
Approved by Health Canada
Shown to shorten washout waiting period and reduce severe bleeding events1
Backed by STAR-T pivotal study and confirmatory real-world evidence from STAR registry
Safe and easy to use in any CPB circuit. Installs in minutes with minimal training or changes to surgical workflow1
GMP manufactured in United States at CytoSorbents ISO 13485 facility
Positive economic value proposition and cost savings for hospitals1,4
DrugSorb™-ATR is based on a hemocompatible, highly porous polymer bead technology that acts like tiny sponges to remove ticagrelor from the blood by pore capture, adsorption, and concentration.
DrugSorb™-ATR installs into any CPB circuit and is safe and easy to use1
- Installs directly into any CPB circuit in minutes
- Starts to work immediately by directly removing onboard ticagrelor
- Solid-state chemistry: no biologics or ligands
- Easy to handle with 1 year shelf life
- Zero device-related serious adverse events observed in pivotal STAR-T study
THE CLINICAL & REAL-WORLD EVIDENCE:
Shorter Washout, Less Bleeding, Fewer Transfusions
DrugSorb™-ATR demonstrated the following effects in isolated CABG patients in the STAR-T pivotal study1,4
3.5x reduction in perioperative bleeding events
Shortened washout period by >50%, enabling timely surgery
Ease-of-use and application in the CPB circuit
Severe Bleeding Events, STAR-T1
Rate of Severe Bleeding After CABG Based on Time from Last Dose (TLD)
Backed by World-Renowned Experts
Michael Mack, MD
U.S. Co-PI Cardiothoracic Surgeon
Chair CV Service Line,
Baylor Scott & White Health
President
Baylor Scott & White Research Institute
Pioneer of the “Heart Team”
C. Michael Gibson, MS, MD
U.S. Co-PI Interventional Cardiologist
Professor of Medicine
Harvard
President & CEO
Baim Institute (formerly the Harvard Clinical Research Institute)
Founder, Editor-In-Chief
www.wikidoc.org
Richard Whitlock, MD, PhD
Canada PI Cardiothoracic Surgeon
Professor of Surgery
McMaster Principal Investigator
Population Health Research Institute
Canada Research Chair
in Cardiovascular Surgery
Potential Conflict of Interest: These KOLs were paid Principal Investigators of the STAR-T Clinical Study.
DrugSorb™-ATR is a potential win for all stakeholders
PATIENTS:
- Minimize delays to definitive surgery
- Reduce serious bleeding risk, which is associated with longer hospital stays and increased morbidity and mortality
SURGICAL TEAMS:
- No change in workflow, seamless integration into the CPB circuit
- Reduce serious perioperative bleeding
- Faster treatment of patients, increased throughput of new patients, reduced expensive and time-consuming re-exploratory surgery
HOSPITAL ADMINISTRATORS:
- Lower cost of care to the hospital for CABG surgery patients by reducing the washout waiting period before surgery
- Reduce post-op bleeding complications, usage of blood products, and length of stay
- Reduced adverse events protects hospital’s quality rating and reputation
Hospital Savings with DrugSorb™-ATR
Surgery at 1.6 days with DrugSorb™-ATR
Cost savings calculated based on washout duration and hospital location. Hospital bed costs as reported in literature.